Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AdaptHealth (AHCO) Cash from Investing Activities (2018 - 2025)

Historic Cash from Investing Activities for AdaptHealth (AHCO) over the last 8 years, with Q3 2025 value amounting to -$92.7 million.

  • AdaptHealth's Cash from Investing Activities fell 7098.27% to -$92.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$265.6 million, marking a year-over-year increase of 1536.74%. This contributed to the annual value of -$310.3 million for FY2024, which is 1315.59% up from last year.
  • As of Q3 2025, AdaptHealth's Cash from Investing Activities stood at -$92.7 million, which was down 7098.27% from $9.6 million recorded in Q2 2025.
  • In the past 5 years, AdaptHealth's Cash from Investing Activities ranged from a high of $9.6 million in Q2 2025 and a low of -$1.2 billion during Q1 2021
  • In the last 5 years, AdaptHealth's Cash from Investing Activities had a median value of -$90.4 million in 2023 and averaged -$162.2 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first crashed by 253639.85% in 2021, then soared by 11181.71% in 2025.
  • Quarter analysis of 5 years shows AdaptHealth's Cash from Investing Activities stood at -$266.2 million in 2021, then surged by 45.24% to -$145.8 million in 2022, then surged by 37.98% to -$90.4 million in 2023, then rose by 3.92% to -$86.9 million in 2024, then dropped by 6.76% to -$92.7 million in 2025.
  • Its Cash from Investing Activities was -$92.7 million in Q3 2025, compared to $9.6 million in Q2 2025 and -$95.6 million in Q1 2025.